Press Releases

Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia Biophytis announced that it has filed for approval on the Food and Drug Administration (FDA) portal to launch its SARA-31 program in the U.S., the first ever Phase 3 study in sarcopenia. The launch of the Phase 3 program follows promising results from the SARA-INT Phase 2b study and discussions with health authorities in 2022. Based on the results of the previous study and feedback from the U.S. government agency, Biophytis is starting its Phase 3 program by filing the first ever Phase 3

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress Biophytis announces that it is taking part in the 16th SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) international congress, a flagship event bringing together experts from all over the world to share thoughts, research and innovations on sarcopenia, cachexia and wasting disorders. Biophytis has given an oral presentation entitled “BIOPHYTIS BIO101 – a candidate treatment for muscle diseases” on the development of Sarconeos (BIO101) for the treatment of sarcopenia. It was made by Cendrine Tourette, PhD in Neuroscience and Director of translational and

Results of the annual general meeting on june 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting. Thanks to the mobilization of shareholders, the AGM could be held with a quorum of more than 26% of the shareholders present or represented. The 10 resolutions presented by the company were approved at a very large majority and were notably comprising the approval of the company’s statutory and consolidated accounts for the fiscal year

Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June Biophytis announces it will participate at the Biotechnology Innovation Organization (BIO) International Convention to be held in Boston from the 5th to the 8th of June 2023, alongside thousands of world leaders in biotechnology and the pharmaceutical industry. Biophytis’ participation in BIO is aligned with the Company’s strategy to partner with global or regional players for its main drug candidates developed in age-related diseases, in particular sarcopenia, and in rare neuromuscular diseases, in particular Duchenne muscular dystrophy. Fullscreen Mode

Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Biophytis announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation (EAA) in France with the French National Authority for Health (HAS) for the use of Sarconeos (BIO101)1 in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate. Following the positive results

Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference Biophytis announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the American Thoracic Society International Conference (ATS 2023) that was held in Washington DC between the 19th and 24th of May 2023. DR Girish Nair, MD – William Beaumont Hospital, Royal Oak, MI 48073, USA and principal investigator of the COVA study in the USA held an oral presentation of the results titled “COVA clinical study: Results from a double-blind, placebo-controlled phase 2-3

Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia Biophytis announced that it has submitted the application for Clinical Trial Authorization (CTA) to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA (European Medicines Agency). The launch of the Phase 3 program follows encouraging results from the SARA-INT Phase 2b study and interactions with health authorities in 2022. Based on the Phase 2b results and feedback from the agencies, Biophytis is starting its Phase 3 programme by filing the first Phase 3 (SARA-31) application in Europe.

Successful capital increase for Biophytis with €2.3 million raised Biophytis is announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders’ preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual investors via the PrimaryBid platform up to €0.4M on the other hand. Stanislas Veillet, CEO of Biophytis stated: “On behalf of Biophytis team, I would like to warmly thank all of the professional investors, historical Company’s investors, for their support, and retail investors through PrimaryBid

Biophytis launches a round of fundraising for approximately 2 million euros Biophytis announced the launch of a round of fundraising for approximately 2 million euros based on issuing new shares for professional investors, as defined below, and retail investors (through the PrimaryBid platform) (the “Operation”). Capital increases as part of a global offering comprising an offer reserved for professional investors and a public offering for retail investors through the PrimaryBid platform. The PrimaryBid offering will close on May 10 2023 at 10pm Paris time and the offering reserved for professional investors will close on May 11, 2023 before start of